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ABSTRACT Control of expression of molecular receptors
for chemical messengers and modulation of these receptors’
activity are now established as ways to alter cellular reaction.
This paper extends these mechanisms to the arena of patho-
logical pain by presenting the hypothesis that increased
expression of a-adrenergic receptors in primary afferent
neurons is part of the etiology of pain in classical causalgia.
It is argued that partial denervation by lesion of peripheral
nerve or by tissue destruction induces a change in peripheral
nociceptors, making them excitable by sympathetic activity
and adrenergic substances. This excitation is mediated by
a-adrenergic receptors and has a time course reminiscent of
experimental denervation supersensitivity. The change in
neuronal phenotype is demonstrable after lesions of mixed
nerves or of the sympathetic postganglionic supply. Similar
partial denervations also produce a substantial increase in
the number of dorsal root ganglion neurons evidencing the
presence of a-adrenergic receptors. The hypothesis proposes
the increased presence of a-adrenergic receptors in primary
afferent neurons to result from an altered gene expression
triggered by cytokines/growth factors produced by disconnec-
tion of peripheral nerve fibers from their cell bodies. These
additional adrenergic receptors are suggested to make noci-
ceptors and other primary afferent neurons excitable by local
or circulating norepinephrine and epinephrine. For central
pathways, the adrenergic excitation would be equivalent to
that produced by noxious events and would consequently
evoke pain. In support, evidence is cited for a form of
denervation supersensitivity in causalgia and for increased
expression of human a-adrenergic receptors after loss of
sympathetic activity.
This essay is an outgrowth of a Colloquium session in which
new evidence was presented on how molecular receptors for
chemical synaptic mediators can specify and regulate neuronal
responses in systems associated with pain mechanisms. These
data build on the concept that not only the nature, but also the
magnitude, of the transfer of information between cells is at
least as much a function of receptive molecules as of the
chemical messengers. Therefore, selective regulation of recep-
tor expression and quantitative control of receptor activity are
factors defining or modulating synaptic function. Importantly,
such concepts, when applied to disease, open novel possibilities
of pharmaceutical manipulation and treatment. My purpose is
to extend such considerations of receptor regulation to a
pathological process involving pain.
There now is considerable agreement that in mammals, the
detection and signaling of tissue damage or pathology, that is,
nociception, is a normal somatosensory function. In this view,
pain, one of the reactions to tissue injury, represents the
sensory concomitant of nociception. By logical extension, pain
in the absence of peripheral tissue damage is abnormal, in
other words, pathological.
Causalgia and Postsympathectomy Pain. S. Weir Mitchell
(1) named a syndrome causalgia after its most prominent
symptom, a burning pain referred to a particular body region
appearing spontaneously or after innocuous stimulation. As
classically described, causalgia appears after partial disruption
of the innervation to a limb, typically after injury to a large
mixed nerve. It probably is relevant that the full-blown syn-
drome is not usually reported after lesions of smaller, purely
cutaneous nerves. Some years after the original descriptions,
Rene Leriche (2) pointed out that the syndrome of causalgia
had features suggesting abnormal sympathetic nervous system
functioning and proposed sympathectomy as a treatment.
Subsequently, the list of disorders in which pain was presum-
ably related to sympathetic nervous activity expanded beyond
the original descriptions of ‘‘classical’’ causalgia and acquired
other terminologies. It is not clear that all of these later
additions to the category of sympathetically related pain
disorders share a common etiology and pathology to the
classical causalgic syndrome. For the purpose of focusing our
consideration on a disorder with a common causative proc-
ess, the following starts from classical causalgia without im-
plying extension to either more general or to more specific
terminologies and classifications: e.g., reflex sympathetic dys-
trophy (3), complex regional pain syndrome (4), and various
others (5).
As outlined in Fig. 1, the classical syndrome of causalgia
includes the following features. (i) It follows partial denerva-
tion of a region, usually by traumatic injury of a large mixed
nerve. (ii) The partially denervated area is hypalgesic. (iii)
Days to weeks after the disturbance of innervation, sponta-
neous pain appears, typically burning in nature, referred to the
partially denervated and nearby regions. (iv) Pain is produced
or increased by normally nonpainful stimuli, e.g., skin cooling
or light touch (allodynia). (v) Abnormal sympathetic function
is evident in the region (e.g., vasomotion, perspiration). (vi)
The pain is aggravated by emotional upset. (vii) Trophic
changes appear in the partially denervated tissues and nearby
regions including abnormal coloration and turgor of the skin,
unusual growth of hair, and changes in bone and other
subcutaneous tissues. Certain of the physical signs are sugges-
tive of chronic inflammation.
After Leriche’s suggestion, regional sympathectomy or re-
gional sympathetic block has been used as a therapy for this
syndrome with, in many cases, at least temporary success (6, 7).
In cases with successful outcome, the abnormal pain is reduced
or abolished, and there is amelioration of trophic changes (2,
6, 7). During remission of the signs and symptoms after
sympathectomy or sympathetic block, local injection of nor-
epinephrine into the skin of the previously painful region has
been reported to recreate the former causalgic pain (ref. 8; see
also ref. 9). These observations suggest that sympathetic
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activity and adrenergic mediators have a part in the aberrant
pain and other features of causalgia.
The connection between adrenergic receptors and the
pathological pain of causalgia proposed herein is circumstan-
tial. The general concepts have been addressed previously (10,
11). Evidence is drawn from experimental studies in animal
models and observations on clinical cases. Admittedly, the
choice of material from the voluminous literature on sympa-
thetically related sensory phenomena is selective. In part, the
selection attempts to avoid mixing disparate material or pos-
sibly different clinical or experimental situations and partially
represents the writer’s view of relevance.
It is important to our argument that in addition to classical
causalgia, there are clinical reports of a painful dystrophy after
regional sympathectomy, usually performed for vascular prob-
lems (12–14). The postsympathectomy painful dystrophies
differ from classical causalgia in that there often is a deep
rather than cutaneous reference for the pain (15). Further-
more, postsympathetic pain is usually described as spontane-
ously remitting, whereas the symptoms of classical causalgia
persist in the absence of a remission produced by sympathec-
tomy.
Adrenergic Responsiveness of Primary Afferent Neurons.
The logic for the proposal that an increased expression of
adrenergic receptors underlies the syndrome of causalgia
begins with observations on the effects of peripherally applied
adrenergic substances on cutaneous nociceptors in vivo. Nor-
epinephrine injected into the skin of normal human beings
does not evoke pain. Prior work had shown that some afferent
fibers terminating in a neuroma at the central stump of a
transected nerve, therefore injured, are excitable by norepi-
nephrine, an effect with a-adrenergic features (16, 17). In
experimental animals, norepinephrine or epinephrine applied
peripherally does not excite nociceptors (18–20). On the other
hand, after injury to part of a mixed peripheral nerve, some of
the nociceptors in the injured nerve become excitable by
sympathetic stimulation and adrenergic substances (20–22).
However, in these experiments the primary afferent elements
exhibiting the adrenergic excitation are not those whose pe-
ripheral fibers had been transected. Furthermore, the adren-
ergically excitable nociceptors are otherwise functionally
equivalent to those found in normal nerve. In rabbit, the
pharmacology of this adrenergic excitation proved consistent
with mediation by a2-adrenergic receptors (20, 21); however,
in primate, other a-adrenergic receptors may be involved (23).
The novel adrenergic excitation of nociceptors is manifest
shortly after the time of nerve injury and persists for months.
Whether other classes of primary afferent neurons also par-
ticipate in the changed response to sympathetic stimuli and
adrenergic substances has not been established. Importantly,
though, regional sympathectomy also has been found to induce
an adrenergically mediated excitation of C-fiber nociceptors,
although features of the adrenergically induced responses after
sympathectomy appear to differ from those seen after mixed
peripheral nerve damage (24).
Adrenergic Receptors and Primary Afferent Neurons. Thus,
the events unleashed by a partial denervation, consisting of
interruption of some peripheral sensory fibers and/or post-
ganglionic sympathetic fibers, alter the phenotype of nocicep-
tors that otherwise remain functionally intact in the injured or
another nerve supplying the region. A clue that this change is
possibly related to an increase in receptor population comes
from the observations that the excitatory effect has a phar-
macological profile of a specific adrenergic a-receptor. More-
over, the time course of the development of the adrenergic
excitation suggested that although it was manifest within a few
days, the peak of excitatory effects is reached 2–3 weeks after
the nerve injury (21). This time course is reminiscent of that
for denervation supersensitivity in which sympathetically de-
nervated organs become much more responsive to adrenergic
agents (25). Sympathetic supersensitivity has been related to
increased numbers of adrenergic receptors (26–28). Moreover,
it is significant that the adrenergic, sympathetic excitation of
nociceptors appears to occur in the region of the peripheral
receptive terminals (21).
We explored the possibility that the appearance of the
excitatory response by cutaneous nociceptors to sympathetic
stimulation and to adrenergic agents is associated with alter-
ations in adrenergic receptors in primary afferent neurons.
The number of dorsal root ganglion (DRG) cells labeled by an
antibody putatively recognizing a2A- adrenergic receptors was
found to markedly increase after both partial and complete
transections of the rat sciatic nerve (29). The principal increase
in the population of DRG neurons expressing this immuno-
reactivity appears in neurons with somata of medium-to-
medium-large diameters (20–40 mm). Double labeling with
markers for injury and growth (c-jun protein) (30, 31) or for
transected fibers (f luorogold) (32) indicated that the increased
immunoreactivity to the a2A-directed antibody occurs both in
injured neurons and in those without evidence of damage. The
latter predominate. The increase in the number of DRG
neurons expressing a2A-adrenergic receptor immunoreactivity
following nerve injury is selective. Increased immunoreactivity
FIG. 2. Prominent adrenergic consequences of partial denerva-
tions.
FIG. 1. Features of causalgia as classically described.
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to the a2A-adrenergic receptor antibody does not appear after
localized artificial inflammation produced by injection of
formalin or Freund’s complete adjuvant, and immunoreactiv-
ity to a a2C antibody is not increased after sciatic nerve injury
(29). An earlier autoradiographic study with the partial a2
agonist, p-iodoclonidine (125I-labeled) had indicated increased
binding in ipsilateral DRG after partial or complete nerve
transection; however, the diameter spectrum of the p-
iodoclonidine-labeled DRG neurons (mainly small-diameter)
partially differs from that with the a2A-adrenergic receptor
antibody (refs. 10 and 29; K. Nishiyama and E.R.P., unpub-
lished data).
An Hypothesis. The effects of experimental nerve injury on
the responsiveness of cutaneous nociceptors to adrenergic
substances and on a-adrenergic receptor expression in dorsal
root ganglia suggest a possible relationship to the etiology and
symptoms of causalgia. The most salient factors are outlined in
Fig. 2. This leads to the hypothesis summarized by Fig. 3. It is
proposed that injury to part of the innervation to a bodily
region, e.g., partial transection of a mixed nerve supplying part
of a limb, induces production of cytokines and/or growth
factors by the injured neurons and associated cells (e.g.,
Schwann cells). These chemical factors, among other effects,
mediate responses to injury or are associated with regrowth
and lead to altered gene expression in uninjured neurons of the
nerve and region. Disconnection of sympathetic postgangli-
onic fibers from their targets, by itself and in conjunction with
injury of primary afferent fibers, contributes to these signals,
leading to altered expression of a-adrenergic receptors. The
fact that classical causalgia usually follows injury to large mixed
nerves raises the possibility that the required lesion for the full
syndrome is the combined interruption of primary afferent
fibers and sympathetic postganglionic fibers. Possibly the loss
of the presence of sympathetic mediators in the vicinity of
primary afferent terminals because of interruption of sympa-
thetic postganglionic fibers is part of the pathophysiological
process. The net result after such partial loss of innervation is
that afferent neurons, normally expressing few a-adrenergic
receptors capable of producing an excitatory response, develop
them. As a result, sensory neurons, particularly nociceptors,
become excitable through these newly formed receptors. The
afferent neuron excitation would occur by norepinephrine
locally released by the remaining sympathetic supply to the
vasculature or norepinephrine and epinephrine circulating
from other parts of the body. For central mechanisms, signals
produced in nociceptors by adrenergic agents are equivalent to
those evoked by noxious events and lead to the sensation of
pain. Signals interpreted as the result of noxious stimuli can
result from activation by a-adrenergic receptors in DRG
neurons by trace quantities of norepinephrine and epineph-
rine. The outcome is spontaneous pain or sensitization of
nociceptors.
Observations on human subjects offer circumstantial sup-
port for facets of this concept. Loss or decrease of sympathetic
activity and the consequent decrease in circulating sympathetic
postganglionic mediators has been shown to increase expres-
sion of a-adrenergic receptors (27, 28, 33). Those observations
were made on blood platelets. By inference, one can argue that
the same process could affect DRG neurons. Regional sym-
pathectomy in experimental animals does increase binding of
a-adrenergic agonists in DRG neurons of the innervated
region (ref. 10 and K. Nishiyama and E.R.P., unpublished
data). Thus, one manipulation that leads to induction of
adrenergic excitation of nociceptors, loss of sympathetic in-
nervation, increases a-adrenergic receptor expression in some
tissues.
It is pertinent that the affected limb in persons suffering
from pain disorders fitting the criteria of classical causalgia
exhibits lower concentrations of norepinephrine and a degra-
dation product (3,4-dihydroxphenylethyleneglycol) in its ve-
nous return than contralaterally. This could imply that the
affected limb has less functioning sympathetic innervation. At
the same time, the affected limb exhibits increased activity by
sympathetically innervated tissues (34, 35). These human data
suggest that a process akin to denervation supersensitivity may
operate in classical causalgia and possibly other varieties of
sympathetically related pain disorders.
To repeat, my suggestion here is that primary afferent
neuron excitation by adrenergic agents in classical causalgia
results from novel a-adrenergic receptor production in dorsal
root ganglia neurons evoked by direct and indirect effects of
injury to peripheral innervation. The increased adrenergic
receptor expression, in part, involves primary afferent neurons,
particularly nociceptors, with intact connections to the periph-
ery and the central nervous system. As a consequence of the
novel a-adrenergic receptor production, some of these afferent
neurons develop an excitatory response to trace amounts of
adrenergic substances in peripheral tissues. Such excitation
would be the start of abnormal signals activating pain pathways
and central pain-related mechanisms.
The concept just outlined, like most hypotheses, has diffi-
culties. First, it cannot explain all parts of a complex syndrome.
In particular, it does not account for the trophic changes,
allodynia, and psychological alterations. The hypothesis sug-
gests only that nerve injury and partial denervation unleash a
set of circumstances leading to an abnormal production of
a-adrenergic receptors in sensory neurons. Experimental stud-
ies suggest that the adrenergic receptor type may be of the a2
(possibly also a1) type (28, 29, 23). These adrenergic receptors
become part of a messenger system whereby adrenergic sub-
stances excite or sensitize peripheral sensory neurons related
to nociception and pain, which represents a step in the process
leading to spontaneous pain and to activation of central
pathways. Subsequently, the abnormally initiated central ac-
tivity can lead to sensitization and other plastic changes in
central neuronal mechanisms. Although not an explanation of
all signs and symptoms of causalgia, this proposal provides a
possible etiology of the pathological process and some insight
into factors that could operate to maintain the process. Sec-
ond, there is the issue of the effects mediated by a2-adrenergic
receptors that usually are presumed in neurons to mediate
FIG. 3. Factors in the hypothesis connecting increased expression
of a-adrenergic receptors to the pain of causalgia.
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inhibitory actions. In this context, it should be remembered
that a2-adrenergic receptors are intermediate arteriolar
smooth muscle constriction. Therefore, this class of receptors
is capable of being part of an excitatory signal-transduction
process (36); furthermore, the signaling system induced by
nerve injury may not be identical to that occurring in neurons
normally.
Does the idea of a change in cellular phenotype by the
enhanced production of membrane receptors possibly apply to
other situations? A similar process could operate in other
versions of sympathetically related pain. It could also relate to
Raynaud’s disease, another pathological process which, in part,
appears to represent overreaction to sympathetic mediators
and could possibly result from an increased expression of
adrenergic receptors (37). Furthermore, enhanced reactions to
adrenergic mediators by the vasculature have also been pos-
tulated for certain forms of hypertension (38, 39). To conclude,
the concept of increased expression of molecular receptors as
a mechanism of disease, and in particular of pathological pain,
deserves serious consideration and further exploration.
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